Last updated on August 2018

Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

Brief description of study

Prospective, multicenter, randomized and open label study evaluating the benefit on renal function at 12 months post-transplantation, with an immunosuppression without calcineurin inhibitor at 3 months and combining mycophenolate sodium-Everolimus versus an immunosuppression combining Everolimus-Tacrolimus, in de novo renal transplant patients.

Clinical Study Identifier: NCT02334488

Find a site near you

Start Over